Cristina Ghenoiu, PhD

Cristina Ghenoiu, PhD, is a partner in Mubadala Capital’s venture business, focusing on biotech investments. Her track record over the past 15 years spans public markets, crossovers, Series A/Bs, as well as company creation and operations. She joined Mubadala in September 2023 and shortly thereafter led their investments into Capstan Therapeutics, acquired by AbbVie for up to $2.1bn in July 2025.

Cristina came to Mubadala from RA Capital, where she was a principal on the venture team (2021-2023). Prior to that, while a vice president on the Biotech Team at Longitude Capital (2016-2020), she helped spin out and raise an $85M series A for Epirium Bio, which she joined and served as Senior Vice President, R&D Operations & New Product Planning (2019-2021). During her time at Longitude and RA she played a key role in financing companies such as Vaxcyte (PCVX), CuraSen, Molecular Templates (MTEM), and venture builds such as 89bio (ETNB), Capacity Bio, GIVAX, Rivus Pharma (scientific co-founder), and Superluminal Medicines.

Before Longitude Capital, Cristina was an associate analyst in biotechnology equity research at TD Cowen (2013-2016) covering publicly traded large and smid cap biotech stocks. Cristina trained as a postdoc at The Rockefeller University, published first author papers in Science, Molecular Cell and JCB; holds a PhD in Chromosome and Cell Biology from Cornell University and a Bachelor of Arts in Biochemistry from Mount Holyoke College, Magna cum laude and High Honors for Computational Quantum Chemistry Thesis.